Shots:

• Arrowhead to receive $40M up front and is eligible to receive ~$660M as potential development- regulatory & commercial milestones- and is further eligible to receive royalties on net product sales
• Horizon to receive a WW exclusive license for ARO-XDH targeting XDH and will be wholly responsible for clinical development and commercialization of the therapy while Arrowhead will conduct all activities through preclinical stages of development
• The collaboration with Horizon further expands its pipeline of RNAi therapeutics by utilizing Arrowhead’s TRiM platform & adds additional program in research and development to discover and develop new therapies

  | Ref: Business Wire | Image: Arrowhead